FDA Approves Braftovi in Combo with Cetuximab for mCRC with BRAF V600E Mutation

On April 8, 2020, the U.S. Food and Drug Administration (FDA) approved encorafenib (Braftovi, Array BioPharma Inc.) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy.

Read FDA announcements.

Posted 4/9/2020